UPC Universe Pharmaceuticals INC Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1809616 · Fiscal year ends 09/30
Financial factors as of 2025-09-30 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-22.4%
TTM net income YoY57.9%
TTM EPS YoY98.7%
Revenue 3-yr CAGR663.4%
Net income 3-yr CAGR—
Margins
Gross margin35.3%
Operating margin-16.3%
Net margin-20.6%
FCF margin-29.8%
EBITDA margin-13.4%
Returns
ROE-7.2%
ROA-5.4%
ROIC (approx.)-12.0%
Asset turnover0.26x
Leverage & solvency
Liabilities / assets19.0%
Debt / equity0.00x
Current ratio4.07x
Interest coverage-10.08x
Cash quality & payout
Operating cash flow / net income1.38x
Accruals ratio2.0%
Payout ratio—
Capex / revenue1.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-30 | FY20242024-09-30 |
|---|---|---|
| Income statement | ||
| Revenue | $17.86B | $23.02B |
| Cost of revenue | $11.56B | $16.95B |
| Gross profit | $6.30B | $6.07B |
| R&D expense | $671.76M | $3.03B |
| SG&A expense | $3.75B | $2.89B |
| Operating income | -$2.92B | -$8.02B |
| Interest expense | $289.38M | $304.52M |
| Pretax income | -$3.67B | -$8.12B |
| Income tax | — | $606.70M |
| Net income | -$3.67B | -$8.73B |
| EBITDA | -$2.40B | -$7.53B |
| EPS (basic) | -8.06 | -626.96 |
| EPS (diluted) | -8.06 | -626.96 |
| Weighted avg. shares (diluted) | 455,871 | 13,920 |
| Balance sheet | ||
| Cash & equivalents | $33.59B | $29.50B |
| Receivables | $13.01B | $12.91B |
| Inventory | $2.19B | $1.74B |
| Current assets | $53.60B | $51.64B |
| PP&E, net | $3.58B | $3.57B |
| Intangibles | $296.79M | $262.88M |
| Total assets | $69.30B | $67.95B |
| Current liabilities | $13.17B | $20.31B |
| Short-term debt | $2.11B | $5.86B |
| Total liabilities | $13.17B | $22.45B |
| Shareholders' equity | $56.13B | $45.50B |
| Shares outstanding | 563,338 | 42,880 |
| Cash flow statement | ||
| Operating cash flow | -$5.05B | -$9.51B |
| Capital expenditure | $266.77M | $208.32M |
| Free cash flow | -$5.32B | -$9.72B |
| Investing cash flow | -$341.81M | -$361.29M |
| Financing cash flow | $9.73B | $33.95B |
| Depreciation & amortization | $517.43M | $485.73M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.